Journal of Nanomedicine & Nanotechnology

Temperature controlled theranostics for pancreatic cancer

6^th Global Experts Meeting on Nanomaterials and Nanotechnology

April 21-23, 2016 Valencia, Spain

Clare Hoskins

Keele University, UK

Scientific Tracks Abstracts: J Nanomed Nanotechnol

Abstract:

Pancreatic cancer is the 4th most aggressive cancer in the western world with less than 34% of patients surviving past 5 years. Lack of specific symptoms results in delayed diagnosis. Theranostics are new platforms, which offer simultaneous diagnosis and therapy resulting in a decrease in treatment time. Here treatments are conjugated onto diagnostics by stimuli responsive binding allowing for controlled drug release resulting in a rapid and localized clinical effect. Hybrid nanoparticles are composed of an iron oxide core surrounded by a rigid gold shell. These particles undergo manipulation due to inherent magnetism of the core whilst laser irradiation of their gold shell results in localized heating due to surface plasmon resonance. Hence, they can be utilized as diagnostics using MRI and laser irradiation can be used as a trigger for drug release. In our studies, we designed hybrid nanoparticles (50 nm) capable of drug loading onto their surface (3:1:0.25, Drug: Fe: Au). By exploiting the gold surface-to-drug interaction of a range of novel Bisnaphtalamido based agents a system with heat triggered drug release was produced. In vitro studies of these formulations on human pancreatic adenocarcinoma cell lines (BxPC-3 & Panc-1) showed the novel formulations possess a 10-fold lower IC50 value when compared with the free drug after only 24 h. These cytotoxicity studies combined with cellular uptake studies showed the formulations to be significantly more effective compared with gemcitabine. In vivo trials have commenced to further elucidate their viability for use as theranostics in pancreatic cancer therapy.

Biography :

Clare Hoskins was appointed as Lecturer in Pharmaceutics at Keele University in 2011. She completed her PhD at the Robert Gordon University, followed by a Post-doc at the University of Dundee. She is a member of the RSC, UKICRS, British Nanomedicine Association and CRS and is a Committee Member of the CRS Preclinical Sciences and Animal Health Committee. She is the Secretary of the RSC Chemical Nanosciences Division. She has published more than 20 papers and serves as an Editorial Board Member for the Journal of Nanomedicine Research.

Email: c.hoskins@keele.ac.uk